How do you manage the severe adverse drug reaction of central serous retinopathy with MEK inhibitors?

If a patient develops central serous retinopathy on a MEK inhibitor despite dose reductions, is it ok to switch to a different BRAF/MEK combination?

Answer from: at Academic Institution

Fortunately, the ICSC-like association of subretinal fluid with MEK inhibitor exposure is usually reversible after cessation of the drug. When working with this class of medications, it is important to coordinate care with the treating oncologist. If a patient presents with subretinal fluid and is ...

Please select the option that best describes you:

How do you manage the severe adverse drug reaction of central serous retinopathy with MEK inhibitors?

Related Questions